1 citations · 1 across the 2 of their papers we have counts for
2 papers
stat.AP2026
Regulatory Considerations for Using Artificial Intelligence Models to Reduce Sample Sizes in Registrational Studies
Aaron M. Smith, Tala Fakhouri, Run Zhuang +1
Applications of artificial intelligence (AI) in drug development continue to increase at a rapid pace. Regulatory authorities have provided increasingly clear perspectives on the u…
stat.AP2026★ 1 cited
Digital Twins as Synthetic Controls in Single-Arm Trials
Daniele Bertolini, Franklin Fuller, Aaron M. Smith +2
Single-arm trials are an important study design for evaluating drug efficacy and safety without enrolling patients into a control arm. Although they do not provide the gold-standar…